Judah Frommer
Stock Analyst at Morgan Stanley
(4.06)
# 534
Out of 5,090 analysts
185
Total ratings
61.03%
Success rate
8.39%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Overweight | $36 | $22.19 | +62.24% | 1 | Dec 1, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $18 → $19 | $13.39 | +41.90% | 2 | Nov 14, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $34 → $37 | $39.84 | -7.13% | 1 | Nov 13, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $71 → $101 | $112.45 | -10.18% | 3 | Sep 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $23.66 | +9.89% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $29.28 | +46.86% | 2 | May 9, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $13.00 | +84.62% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $31.53 | -30.23% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $10.89 | -44.90% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $67.94 | +56.02% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $18.31 | +91.15% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $2.04 | +537.35% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.38 | +26.05% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.76 | +2,172.73% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.89 | +587.83% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $71.77 | -58.20% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $31.85 | -27.79% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $77.62 | -35.58% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $22.24 | +534.14% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $4.40 | +104.55% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $34.94 | -37.03% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.23 | +33.84% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $9.35 | -14.44% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $86.86 | -47.04% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $3.73 | +87.67% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $21.29 | +158.34% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $205.47 | -77.61% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $90.83 | -46.05% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $897.75 | -58.79% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $75.52 | -58.95% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $73.49 | +3.42% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $133.70 | +36.13% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $124.64 | -14.15% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $122.27 | -22.30% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.32 | +3.96% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $175.55 | -33.92% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $91.49 | -58.47% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $86.21 | -74.48% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $63.29 | -44.70% | 9 | Apr 29, 2020 |
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $22.19
Upside: +62.24%
Trevi Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $13.39
Upside: +41.90%
Zenas BioPharma
Nov 13, 2025
Maintains: Overweight
Price Target: $34 → $37
Current: $39.84
Upside: -7.13%
ABIVAX Société Anonyme
Sep 12, 2025
Maintains: Overweight
Price Target: $71 → $101
Current: $112.45
Upside: -10.18%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $23.66
Upside: +9.89%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $29.28
Upside: +46.86%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $13.00
Upside: +84.62%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $31.53
Upside: -30.23%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $10.89
Upside: -44.90%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $67.94
Upside: +56.02%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $18.31
Upside: +91.15%
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.04
Upside: +537.35%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.38
Upside: +26.05%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.76
Upside: +2,172.73%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.89
Upside: +587.83%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $71.77
Upside: -58.20%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $31.85
Upside: -27.79%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $77.62
Upside: -35.58%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $22.24
Upside: +534.14%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $4.40
Upside: +104.55%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $34.94
Upside: -37.03%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.23
Upside: +33.84%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $9.35
Upside: -14.44%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $86.86
Upside: -47.04%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $3.73
Upside: +87.67%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $21.29
Upside: +158.34%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $205.47
Upside: -77.61%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $90.83
Upside: -46.05%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $897.75
Upside: -58.79%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $75.52
Upside: -58.95%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $73.49
Upside: +3.42%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $133.70
Upside: +36.13%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $124.64
Upside: -14.15%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $122.27
Upside: -22.30%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.32
Upside: +3.96%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $175.55
Upside: -33.92%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $91.49
Upside: -58.47%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $86.21
Upside: -74.48%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $63.29
Upside: -44.70%